Winter boots are difficult to pack, but their bulky size can be used to your advantage. Here's how to pack your boots for ...

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...

Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew ...

Eli Lilly’s (LLY) shares slumped over 8% on Tuesday after the company projected fourth-quarter sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro to fall short of Wall Street ...

Lilly's stock went on a tear in the beginning of 2023, with the company's shares doubling as investors bet on the drug's popularity. The stock stumbled in October last year, after Zepbound's sales ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...

STORY: Shares of Eli Lilly tumbled as much as 8% on Tuesday, after the company forecast weaker-than-expected fourth-quarter sales of its weight-loss drug Zepbound. The decline put the stock on ...

Like many other biopharma companies presenting at this year’s J.P. Morgan Healthcare Conference, Eli Lilly took a chance on Tuesday to share its preliminary sales results for 2024. Unfortunately ...

Shares of Eli Lilly & Co. were headed for their worst day ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

Only in the crazy sector of metabolic medicines can 32% revenue growth be considered a disappointment. That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the ...

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...